Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer

British Journal of Cancer

Volumn 97, Issue 4, 2007, Pages 464-471

  Goldstein, D ^a   Van Hazel, G ^b   Walpole, E ^c   Underhill, C ^d   Kotasek, D ^e   Michael, M ^f   Shapiro, J ^g   Davies, T ^h   Reece, W ^h   Harvey, J ^c   Spry, N ^b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d Border Medical Oncology Australia   (Australia)

^e Ashford Cancer Centre   (Australia)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g ALFRED HOSPITAL   (Australia)

^h ELI LILLY AUSTRALIA PTY LTD   (Australia)

Author keywords

Conformal radiation; Gemcitabine; Locally advanced; Pancreas cancer

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; CANCER CONTROL; CANCER GROWTH; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INOPERABLE CANCER; INTESTINE OBSTRUCTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SAFETY; SURVIVAL RATE; SURVIVAL TIME; THREE DIMENSIONAL IMAGING; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; IMAGING, THREE-DIMENSIONAL; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIOTHERAPY, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34547907771     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603900     Document Type: Article

References (35)

1. Berlin JD, Catalano P, Thomas JP, Jugler JW, Haller DG, Bowen Benson III A (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270-3275
2. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA (2003) Cancer and leukaemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 34: 107-116
3. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413
4. Cardenes HR, Chiorean EG, DeWitt J, Schmidt M, Loehrer P (2006) Locally advanced pancreatic cancer: current therapeutic approach. Oncologist 11: 612-623
5. Chauffert B, Mornex F, Bonnetain F, Triboulet JP, Bouche O, Rougier P, Bosset JF, Aparicio T, Masskouri F, Bedenne L (2006) Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: a FFCD-SFRO study. J Clin Oncol 24(18S): 4008; (abstract)
6. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M (2002) Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologico dell'Italia Meridonale. Cancer 94: 902-910
7. Cunningham D, Chau I, Stocken D, Davies C, Dunn J, Valle J, Smith D, Steward W, Harper P, Neoptolemos J (2005) Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer Suppl 3: 12; (abstract PS11)
8. Dickler A, Abrams RA (2005) Radiochemotherapy in the management of pancreatic cancer-Part II: use in adjuvant and locally unresectable settings. Semin Rad Oncol 15: 235-244
9. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21: 109-122
10. Ferrone CR, Finklestein DM, Thayer SP, Muzikansky A, Feranandez-del Castillo C, Warshaw AL (2006) Perioperative CA 19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 24: 2897-2902
11. Gastrointestinal Tumor Study Group (1985) Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 56: 2563-2568
12. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Svensson C (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7: 593-600
13. Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, de Gramont A, Louvet C (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25: 326-331
14. ICRU (1993) Report No. 50, Prescribing, Recording, and Reporting Photon Beam Therapy. Bethesda, MD: International Commission on Radiation Units and Measurements
15. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer Statistics, 2005. CA Cancer J Clin 55: 10-30
16. Lopes G, Rocha Lima CM (2005) Docetaxel in the management of advanced pancreatic cancer. Semin Oncol 32(Suppl 4): S10-S23
17. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23: 3509-3516
18. Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, Iveson T, O'Brien M, Tebbutt N, Harrington A, Hill M (2002) Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 20: 3130-3136
19. Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D (2005) CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 93: 740-743
20. Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, Hagan K, Greenberg B, Colwell B, Zee B, Tu D, Ottaway J, Humphrey R, Seymour L (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21: 3296-3302
21. Moureau-Zabotto L, Phélip J, Afchain P, Mineur L, André T, Vendrely V, Lledo G, Dupuis O, Touboul E, Balosso J (2006) Concomitant administration of weekly oxaliplatin, 5FU continuous infusion and radiotherapy in locally advanced pancreatic cancer (LAPC): a GERCOR phase II study. J Clin Oncol 24(18S): 4039
22. Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M, Kindler HL (2005) A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16: 1639-1645
23. Osborne C, Bydder SA, Ebert MA, Spry NA (2006) Comparison of noncoplanar and coplanar irradiation techniques to treat cancer of the pancreas. Austral Radiol 50: 463-467
24. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81: 882-885
25. Petty RD, Nicolson MC, Skaria S, Sinclair TS, Samuel LM, Koruth M (2003) A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity. Ann Oncol 14: 1100-1105
26. Poplin E, Levy DE, Berlin J, Rothenberg M, Cella D, Mitchell E, Alberts S, Benson III A (2006a) Phase III trial of gemcitabine (30-min infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 24(18S): LBA4004; (abstract)
27. Poplin E, Levy DE, Berlin J, Rothenberg M, Cella D, Mitchell E, Alberts S, Benson III A (2006b) Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine+ oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/? vgnextoid1/476f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=40&abstractID=30905
28. Rana V, Krishnan S, Abbruzzese JL, Xiong HQ, Varadhachary GR, Ho L, Janjan NA, Evans DB, Wolff RA, Crane CH (2006) Neoadjuvant chemotherapy improves outcomes of chemoradiation therapy for locally advanced pancreatic cancer. J Clin Oncol 24(18S): 4036
29. Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, Small Jr W, Safran H, Wanebo HJ (2004) Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 27: 51-56
30. Rocha Lima CM, Green MR, Rotche R, Miller Jr WH, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22: 3776-3783
31. Roldan GE, Gunderson LL, Nagorney DM, Martin JK, Ilstrup DM, Holbrook MA, Kvols LK, McIlrath DC (1988) External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 61: 1110-1116
32. Whittington R, Solin L, Mohiuddin M, Cantor RI, Rosato FE, Bierman WA, Weiss SM, Pajak TF (1984) Multimodality therapy of localized unresectable pancreatic adenocarcinoma. Cancer 54: 1991-1998
33. Wilkowski R, Thoma M, Bruns C, Wagner A, Heinemann V (2006) Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer. J Pancreas 7: 349-360
34. Wilkowski R, Thoma M, Weingandt H, Dühmke E, Heinemann V (2005) Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose. J Pancreas 6: 216-230
35. Willett CG, Czito BG, Bendell JC, Ryan DP (2005) Locally advanced pancreatic cancer. J Clin Oncol 23: 4538-4544